Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Total Voting Rights

1 Dec 2025 15:00

RNS Number : 7258J
GSK PLC
01 December 2025
 

Issued: 1 December 2025, London UK

 

Total Voting Rights

 

 

 

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 30 November 2025 consisted of 4,315,433,684 shares of 31 ¼ pence each ('Ordinary Shares'), of which 236,608,577 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 4,078,825,107. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Notifications may be sent to company.secretary@gsk.com.

 

 

V A Whyte

Company Secretary

 

1 December 2025

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBXBDDDDGDGUB
Date   Source Headline
12th Jun 202511:00 amPRNDirector/PDMR Shareholding
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20253:30 pmRNSDirector/PDMR Shareholding
11th Jun 20257:00 amRNSTransaction in Own Shares
10th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSGSK - second tranche of share buyback programme
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20253:30 pmRNSDirector/PDMR Shareholding
2nd Jun 20253:00 pmRNSTotal Voting Rights
2nd Jun 20257:00 amRNSLinerixibat file accepted for review by US FDA
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 202512:00 pmRNSGSK stops Phase 3 trial on cUTIs for efficacy
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 202512:16 pmRNSpositive CHMP opinion on Blenrep in EU
23rd May 20257:00 amRNSFDA approves Nucala COPD indication
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20253:30 pmRNSDirector/PDMR Shareholding
20th May 20257:00 amRNSTransaction in Own Shares
19th May 20257:00 amRNSBlenrep for 2L+ multiple myeloma approved in Japan
19th May 20257:00 amRNSTransaction in Own Shares
16th May 20257:00 amRNSTransaction in Own Shares
15th May 20257:00 amRNSTransaction in Own Shares
14th May 20257:00 amRNSGSK to acquire efimosfermin
14th May 20257:00 amRNSTransaction in Own Shares
13th May 20253:30 pmRNSDirector/PDMR Shareholding
13th May 202512:56 pmRNSUpdate on belrestotug development programme
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20253:31 pmRNSBlock listing Interim Review
12th May 20257:00 amRNSTransaction in Own Shares
9th May 20257:00 amRNSTransaction in Own Shares
8th May 20255:15 pmRNSDirector/PDMR Shareholding
8th May 20253:30 pmRNSDirector/PDMR Shareholding
8th May 202511:15 amRNSLinerixibat GLISTEN pIII trial data at EASL
8th May 20257:00 amRNSTransaction in Own Shares
7th May 20256:22 pmRNSResult of AGM
7th May 20257:00 amRNSTransaction in Own Shares
6th May 20257:00 amRNSTransaction in Own Shares
2nd May 20257:00 amRNSTransaction in Own Shares
1st May 20253:30 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
1st May 20257:00 amRNSNucala MATINEE data in COPD published in NEJM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.